The Limited Times

Now you can see non-English news...

Stéphane Bancel, French biotech star


PORTRAIT - While the South African variant Omicron worries, the boss of Moderna has already put his research teams on the trail of a new vaccine capable of resisting it.

Stéphane Bancel is more than ever under pressure, while the South African variant of Covid-19, Omicron, particularly contagious, has been sowing panic on the planet for several days. After having succeeded in the incredible gamble of developing a vaccine in record time, from 2020, using revolutionary messenger RNA technology, after having shipped 700 million doses worldwide in 2021, Moderna is was about to move up a gear by producing up to 3 billion vaccines in 2022.

"I do not know of any other industry which has had to make such an extraordinary rise in such a short time",

recently congratulated the 49-year-old CEO.

And now the Omicron variant demonstrates what many feared: even vaccinated, humans remain under the threat of surprise and multiple mutations of the coronavirus such as those characterizing Omicron.

Read also

Covid-19: Moderna will set up a first vaccine plant in Africa

In an interview with the

Financial Times

this week, Stéphane Bancel also confided to fear

This article is for subscribers only.

You have 77% left to discover.

To cultivate one's freedom is to cultivate one's curiosity.

Continue reading your article for € 1 the first month


Already subscribed?

Log in

Source: lefigaro

All business articles on 2021-12-03

You may like

Trends 24h


© Communities 2019 - Privacy